Join Zoom Meeting
https://mc-meet.zoom.us/j/95869608121?pwd=NG9GaG5JWE44eGpSckdRWHFSNnVkUT09

Meeting ID: 958 6960 8121
Passcode: 636276

Visiting Faculty
Scott Plotkin, M.D., Ph. D.
“Next generation clinical trials for schwannomatosis: platforms for drug discovery in rare neurologic conditions”

Learning objectives: 
Upon conclusion of this activity, participants will be able to:

• Differentiate types of schwannomatosis and describe key clinical features associated with subgroup of disorders
• Give examples of barriers for clinical trials of rare neurologic diseases
• Identify features of novel clinical trials designs such as basket and platform trials

Dr. Plotkin does have the following relevant financial relationships to disclose: Consulting: Nflection Therapeutics; Other for-Profit: Akouos; Grant/Research: Takeda; Stock, stock options, warrant: NflectionTherapeutics, NF2 Therapeutics, and does intend to discuss the following off-label/investigative use of Pharmaceuticals or Instruments: Takeda-Brigatinib; Puma Biotechnology-Neratinib; Recordati-Siltuximab; Amgen-Erenumab-aooe; Roche-Bevacizumab; GlaxoSmithKline-Lapatinib; Novartis-Everolimus; Pfizer-Axitinib, crizotinib; AstraZeneca-Selumetinib; Zhejiang Bata Pharma-Icotinib.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.